Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy of ALXN1840 on human biliary copper excretion quantified with 64CuCl2 PET/MR-scan

Next Previous
X
Search
Trial Profile

Efficacy of ALXN1840 on human biliary copper excretion quantified with 64CuCl2 PET/MR-scan

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tiomolibdate choline (Primary)
  • Indications Hepatolenticular degeneration
  • Focus Pharmacokinetics
  • Acronyms ALXN1840WD-Cu-Excretion

    • Most Recent Events

    • 09 Dec 2023 Results from EudraCT2020-005832-31 and EudraCT 2021-000102-25 , investigating the effects of TTM on copper absorption and biliary excretion published in the Journal of Hepatology
    • 01 Jul 2022 Status changed from recruiting to completed.
    • 28 Apr 2021 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top